These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35297026)

  • 1. Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain.
    Osumili B; Artime E; Mitchell B; Rubio-de Santos M; Díaz-Cerezo S; Giménez M; Spaepen E; Sharland H; Valentine WJ
    Diabetes Ther; 2022 Apr; 13(4):775-794. PubMed ID: 35297026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.
    Pöhlmann J; Mitchell BD; Bajpai S; Osumili B; Valentine WJ
    J Diabetes Sci Technol; 2019 Sep; 13(5):910-918. PubMed ID: 30700165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.
    Hinahara J; Weinzimer SA; Bromley ER; Goss TF; Kendall DM; Hammer M
    J Manag Care Spec Pharm; 2022 Apr; 28(4):461-472. PubMed ID: 35332789
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis.
    Yale JF; Osumili B; Mitchell BD; Hunt B; Sohi G; Jeddi M; Mojdami D; Valentine WJ
    J Med Econ; 2022; 25(1):238-248. PubMed ID: 35094622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE.
    Settles JA; Gerety GF; Spaepen E; Suico JG; Child CJ
    Endocr Pract; 2020 Apr; 26(4):407-415. PubMed ID: 32293921
    [No Abstract]   [Full Text] [Related]  

  • 6. A ready-to-use liquid glucagon for treatment of severe hypoglycemia demonstrates reduced healthcare payer costs in a budget impact model.
    Leinwand B; Johnsrud M; Nguyen A; Meyer J; Johnson K
    J Med Econ; 2020 Jul; 23(7):744-750. PubMed ID: 32162983
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversations and Reactions Around Severe Hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers.
    Ampudia-Blasco FJ; Artime E; Díaz S; Rubio M; Reviriego J; Mitchell B; Osumili B; Peyrot M; Pokrzywinski R; Spaepen E; Snoek F
    Endocrinol Diabetes Nutr (Engl Ed); 2021 Oct; 68(8):557-566. PubMed ID: 34872639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Economic Burden of Insulin-Related Hypoglycemia in Spain.
    Parekh W; Hoskins N; Baker-Knight J; Ramirez de Arellano A; Mezquita Raya P
    Diabetes Ther; 2017 Aug; 8(4):899-913. PubMed ID: 28653237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversations and reactions around severe hypoglycemia (CRASH) global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers: Findings from the French cohort.
    Chevalier N; Penfornis A; Riveline JP; Chartier F; Mitchell B; Osumili B; Spaepen E; Snoek F; Peyrot M; Benabbad I
    Ann Endocrinol (Paris); 2022 Feb; 83(1):16-26. PubMed ID: 34871601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. People With Diabetes and Caregivers Prefer Rescue Glucagon Treatment With a Wider Storage Temperature Range and a Nasal Administration, When Efficacy is Similar: A Discrete Choice Experiment in Spain.
    Mitchell BD; Rentz AM; Kummer S; Yan Y; Heidenreich S; Krucien N; Artime E; Osumili B; Rubio M; Gelhorn HL
    J Diabetes Sci Technol; 2023 Nov; 17(6):1623-1633. PubMed ID: 35533142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.
    Deeb LC; Dulude H; Guzman CB; Zhang S; Reiner BJ; Piché CA; Pradhan S; Zhang XM
    Pediatr Diabetes; 2018 Aug; 19(5):1007-1013. PubMed ID: 29512902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the Local Impact of Hypoglycemia Tool.
    Hoskins N; Tikkanen CK; Pedersen-Bjergaard U
    J Med Econ; 2017 Apr; 20(4):363-370. PubMed ID: 27926814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia: Pooled Analysis of Clinical Trials.
    Seaquist E; Giménez M; Yan Y; Matsuhisa M; Kao CY; Wadwa RP; Nagai Y; Khunti K
    J Endocr Soc; 2024 Feb; 8(4):bvae034. PubMed ID: 38444629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia.
    Giménez M; Khunti K; Matsuhisa M; Chenji S; Syring K; Yan Y
    Diabetes Ther; 2023 Nov; 14(11):1757-1769. PubMed ID: 37707700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Healthcare Services Following Severe Hypoglycemia in Patients with Diabetes: Analysis of Real-World Data.
    Goldstein D; Chodick G; Shalev V; Thorsted BL; Elliott L; Karasik A
    Diabetes Ther; 2016 Jun; 7(2):295-308. PubMed ID: 27101312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
    Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
    Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal Glucagon Is Easier to Use and More Preferred and Needs Less Effort to Administer Than Injectable Glucagon: User Perceptions of Glucagon Administration During Severe Hypoglycemia Simulation.
    Settles J; Hinnen D; Spaepen E; Bajpai S; Turakhiya A; Ghodke S; Child CJ
    Endocr Pract; 2022 May; 28(5):486-493. PubMed ID: 35263661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.
    Mezquita-Raya P; Ramírez de Arellano A; Kragh N; Vega-Hernandez G; Pöhlmann J; Valentine WJ; Hunt B
    Diabetes Ther; 2017 Apr; 8(2):401-415. PubMed ID: 28224463
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.